KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Revenue (2019 - 2025)

GoodRx Holdings' Revenue history spans 7 years, with the latest figure at $194.8 million for Q4 2025.

  • For Q4 2025, Revenue fell 1.91% year-over-year to $194.8 million; the TTM value through Dec 2025 reached $796.9 million, up 0.57%, while the annual FY2025 figure was $796.9 million, 0.57% up from the prior year.
  • Revenue for Q4 2025 was $194.8 million at GoodRx Holdings, down from $196.0 million in the prior quarter.
  • Across five years, Revenue topped out at $213.3 million in Q4 2021 and bottomed at $160.4 million in Q1 2021.
  • The 5-year median for Revenue is $195.2 million (2021), against an average of $192.6 million.
  • The largest annual shift saw Revenue skyrocketed 43.26% in 2021 before it decreased 13.67% in 2022.
  • A 5-year view of Revenue shows it stood at $213.3 million in 2021, then decreased by 13.67% to $184.1 million in 2022, then rose by 6.81% to $196.6 million in 2023, then increased by 0.99% to $198.6 million in 2024, then fell by 1.91% to $194.8 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Revenue are $194.8 million (Q4 2025), $196.0 million (Q3 2025), and $203.1 million (Q2 2025).